NanOlogy, a clinical-stage oncology company developing intratumoral therapies using its Large Surface Area Microparticle (LSAM) approach, said it has appointed John M. Goldberg, MD as fractional chief medical officer to help advance its preclinical and clinical investigational drug portfolio, including a program targeting diffuse intrinsic pontine glioma.
Goldberg is board-certified in pediatric hematology/oncology and brings more than 20 years of experience across drug development, from early research through late-stage clinical trials, the company said. His previous chief medical officer roles include positions at Rafael Holdings and Oncorus, and earlier he served in medical leadership roles at H3 Biomedicine and Agenus, according to the announcement. NanOlogy said Goldberg has also held academic appointments at Harvard Medical School and the University of Miami Miller School of Medicine.
NanOlogy said the appointment supports its plan to progress its DIPG program toward initiating a clinical trial in late 2026 and to move its clinical-stage investigational drugs for adult solid tumors into later-stage studies. The company’s LSAM platform is designed to enable direct local delivery of “pure drug” to tumors, with the goal of improving response while minimizing systemic toxicity.
KEY QUOTES:
“As we progress our DIPG program toward initiating a clinical trial in late 2026 and advance our clinical-stage investigational drugs into late-phase clinical trials, John will play a critical role in our development strategy and execution. John’s broad expertise across both drug development and business strategy will strengthen our ability to rapidly advance these programs.”
David Arthur, CEO, NanOlogy
“I am impressed by NanOlogy’s progress and believe my experience, including development of intratumoral therapies, positions me well to contribute to NanOlogy’s future success. My initial priorities are to advance the DIPG program and select the best clinical pathway for our adult solid tumor investigational drugs. I am looking forward to our progress and the benefit it may hold for cancer patients.”
John M. Goldberg, MD, Fractional Chief Medical Officer, NanOlogy
